Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Alto Neuroscience Inc

ANRO ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NYSE · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$25.31

▼ -0.86%

Market Cap $993.22M · Vol 182.33K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$993.22M

Small Cap

Div Yield

N/A

EPS Growth

-27.15%

YoY

RSI (14)

16.58

Momentum

Beta

N/A

vs Market

52W High

$37.40

32.33% below

52W Low

$4.04

526.49% above

Volume

182.33K

Avg 201.23K

P/B

3.76

Price-to-book

ROE

N/A

Return on equity

Free Float

91.17%

Public shares

Shariah Compliance8 STANDARDS

✗ Alto Neuroscience Inc (ANRO) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ANRO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.88%

-28.10%

+1.48%

+8.12%

YTD

+42.19%

+521.87%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-63,238,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-34.92% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.76
P/FCF	N/A
EPS Growth	-27.15%
Outstanding Shares	39.24M

Technical Indicators

50-Day SMA	$30.94
200-Day SMA	$23.68
RSI (14)	16.58
Beta	N/A
52-Week High	$37.40
52-Week Low	$4.04

Volume Today	182.33K
Avg Daily Volume (30D)	201.23K
Relative Volume	0.91x
Volatility (10D)	54.45
Volatility (30D)	50.56
Free Float	91.17%

Analyst Consensus

STRONG BUY

Current Price $25.31

Mean Target $38.11

52W Low$4.04 52W High$37.40

Current

Target

$4.04 $37.40

Current Analyst target

+50.58% upside potential · 11 analysts

Identifiers

ExchangeNYSE

FIGIBBG00WYFS6S4

ISINUS02157Q1094

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -2.54% ONC BeOne Medicines AG -1.96% 068270.KS Celltrion, Inc. +3.32% MEDP Medpace Holdings, Inc. -4.18% ABVX Abivax SA -3.96%

Company Profile

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.